Implementation of “clinical sequencing” in cancer genome medicine in Japan
Author:
Open Access
- 2 February 2018
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 109 (3) , 507-512
Abstract
In oncology, actionable mutations (alterations) in cancer‐associated genes are critical in terms of the selection of therapeutic approaches. Next‐generation sequencing of tumor sample DNA (ie, clinical sequencing) can guide clinical management by providing diagnostic or prognostic data, and facilitating the identification of potential treatment regimens, such as molecular‐targeted and immune checkpoint blockade therapies. In the USA, a variety of tumor‐profiling multiplex gene panels have been developed and implemented for this purpose. In Japan, several academic institutions have now carried out detailed investigations of the feasibility and value of clinical sequencing, and cancer societies have issued consensus clinical practice guidance for next‐generation sequencing‐based gene panel tests. These efforts will facilitate the implementation of cancer genome medicine in Japan.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP17kk0205004, JP17lk1403003)
This publication has 34 references indexed in Scilit:
- A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancerScience Translational Medicine, 2017
- Actionable secondary findings from whole-genome sequencing of 954 East AsiansHuman Genetics, 2017
- The current status and problems confronted in delivering precision medicine in Japan and EuropeCurrent Problems in Cancer, 2017
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in CancerThe Journal of Molecular Diagnostics, 2017
- Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid TumorsJAMA Oncology, 2016
- Evolution of frameworks for expediting access to new drugs in JapanNature Reviews Drug Discovery, 2016
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaNew England Journal of Medicine, 2014
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung CancerNew England Journal of Medicine, 2014
- Tumor sequencing takes off, but insurance reimbursement lagsNature Medicine, 2014